ANI Pharmaceuticals
ANIP · Pharmaceuticals
$72.61
1.5%Collegium Pharmaceutical
COLL · Pharmaceuticals
$22.96
2.3%The short version
- ANI Pharmaceuticals is the larger business, with $883M of revenue in fiscal 2025 against $781M for Collegium Pharmaceutical.
- ANI Pharmaceuticals grew revenue faster (43.8%, against 23.6%).
- Collegium Pharmaceutical kept more of each dollar of sales as operating profit (23.0% operating margin, against 12.6% operating margin).
- Collegium Pharmaceutical turned more of its sales into free cash flow (42.0% FCF margin, against 19.4% FCF margin).
- Collegium Pharmaceutical earned a higher return on the capital invested in it (53.4%, against 15.9%).
- Investors pay more for each dollar of Collegium Pharmaceutical’s earnings: a P/E of 18.5x against 15.7x for ANI Pharmaceuticals.
| Latest fiscal year | ANIP · FY25 | COLL · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.6B | $746M |
| Revenue | $883M | $781M |
| Free cash flow | $171M | $328M |
| Net income | $78.3M | $62.9M |
| Growth | ||
| Revenue growth | 43.8% | 23.6% |
| 5-year growth | 33.5% | 20.3% |
| Share count change | 9.9% | −1.8% |
| Profitability | ||
| Gross margin | — | 59.4% |
| Operating margin | 12.6% | 23.0% |
| Net margin | 8.9% | 8.1% |
| FCF margin | 19.4% | 42.0% |
| Return on capital | 15.9% | 53.4% |
| Return on equity | 16.6% | 23.7% |
| Balance sheet | ||
| Net debt | $23.7M | −$149M |
| Net debt / EBITDA | 0.1x | −0.4x |
| Dividends and buybacks | $13.4M | $25.1M |
| Valuation & quality | ||
| P/E | 15.7x | 18.5x |
| Piotroski F-score | 6 | 6 |
FY16
ANIP $129M
COLL $1.7M
FY17
ANIP $177M
COLL $28.5M
FY18
ANIP $202M
COLL $280M
FY19
ANIP $207M
COLL $297M
FY20
ANIP $209M
COLL $310M
FY21
ANIP $216M
COLL $277M
FY22
ANIP $316M
COLL $464M
FY23
ANIP $487M
COLL $567M
FY24
ANIP $614M
COLL $631M
FY25
ANIP $883M
COLL $781M
ANIP
COLL
FY16
ANIP 15.6%
COLL −5,498.7%
FY17
ANIP 16.0%
COLL −265.0%
FY18
ANIP 17.5%
COLL −7.4%
FY19
ANIP 7.9%
COLL −8.0%
FY20
ANIP −7.7%
COLL 18.1%
FY21
ANIP −18.4%
COLL 6.4%
FY22
ANIP −11.2%
COLL 7.2%
FY23
ANIP 9.7%
COLL 29.5%
FY24
ANIP 0.1%
COLL 26.9%
FY25
ANIP 12.6%
COLL 23.0%
ANIP
COLL
FY16
ANIP $22.9M
COLL −$75.5M
FY17
ANIP $29.1M
COLL −$68.0M
FY18
ANIP $61.3M
COLL $164M
FY19
ANIP $39.0M
COLL $21.3M
FY20
ANIP $9.1M
COLL $88.4M
FY21
ANIP $0.8M
COLL $102M
FY22
ANIP −$40.1M
COLL $123M
FY23
ANIP $110M
COLL $274M
FY24
ANIP $47.8M
COLL $203M
FY25
ANIP $171M
COLL $328M
ANIP
COLL
FY16
ANIP 5.3%
COLL —
FY17
ANIP 5.3%
COLL —
FY18
ANIP 11.0%
COLL —
FY19
ANIP 5.8%
COLL —
FY20
ANIP −3.6%
COLL —
FY21
ANIP −7.0%
COLL 10.4%
FY22
ANIP −5.2%
COLL 16.5%
FY23
ANIP 8.5%
COLL 68.7%
FY24
ANIP 0.1%
COLL 53.0%
FY25
ANIP 15.9%
COLL 53.4%
ANIP
COLL
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.